Xencor | XNCR - Selling And Administration Expenses


Xencor reported $17.04M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
J&J USD 6.75B 831M Dec/2025
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Merck USD 2.85B 215M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Xencor USD 17.04M 70.74M Dec/2025